4D Molecular Therapeutics, Inc. (FDMT) – What Are Analysts Thinking About This Stock?

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been assigned an average rating of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and ten have assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $30.22.

Several equities analysts recently weighed in on the stock. B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Thursday, October 15th. Chardan Capital lowered their target price on shares of 4D Molecular Therapeutics from $26.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, October 6th. Bank of America upped their target price on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the company a “buy” rating in a research report on Tuesday, September 29th. Finally, Citigroup reissued a “buy” rating on shares of 4D Molecular Therapeutics in a research note on Thursday, October 22nd.

Insider Activity at 4D Molecular Therapeutics

In related news, insider David Kirn sold 58,333 shares of 4D Molecular Therapeutics stock in a transaction on Monday, October 5th. The stock was sold at an average price of $12.92, for a total transaction of $753,662.36. Following the completion of the sale, the insider directly owned 709,153 shares of the company’s stock, valued at $9,162,256.76. The trade was a 7.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 122,155 shares of company stock worth $1,635,925 over the last ninety days. 7.90% of the stock is owned by insiders.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Toth Financial Advisory Corp bought a new position in 4D Molecular Therapeutics during the third quarter worth about $29,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter valued at about $40,000. Legal & General Group Plc bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at about $59,000. China Universal Asset Management Co. Ltd. raised its position in shares of 4D Molecular Therapeutics by 21.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,080 shares of the company’s stock valued at $146,000 after acquiring an additional 1,760 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at approximately $148,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

4D Molecular Therapeutics stock opened at $12.99 on Friday. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics has a 1 year low of $6.96 and a 1 year high of $16.93. The company has a market cap of $717.62 million, a PE ratio of -4.94 and a beta of 2.92. The company’s 50-day moving average is $13.25 and its two-hundred day moving average is $11.03.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The business had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. Equities analysts anticipate that 4D Molecular Therapeutics will post -4.14 earnings per share for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc. is a biotechnology company developing genetic medicines for serious diseases. Its research focuses on adeno-associated virus (AAV) gene therapies, which use engineered viral vectors to deliver therapeutic genetic material to cells. The company’s proprietary Therapeutic Vector Evolution platform is designed to create AAV vectors with targeted properties, including the ability to reach specific tissues. Its investigational programs have included treatments for retinal diseases, cystic fibrosis and Fabry disease.